Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoCath CE-marks 7F cardiac cryoablation device:

This article was originally published in Clinica

Executive Summary

Canada's CryoCath Technologies has CE-marked for sale in Europe its 7F Freezor catheter cryoablation system for treating cardiac tachyarrhythmias (rapid and irregular heartbeats). As well as being smaller and easier to handle than the company's earlier 9F Freezor product, which was CE-marked last year, the 7F system provides 40% more cooling capacity to treat tachyarrhythmias faster and more effectively, Steve Arless, CryoCath's president and CEO, told Clinica. The new product will be introduced into 20 leading centres this year, with a more widespread commercial launch planned for 2002, says the Kirkland, Quebec firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel